Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Eplerenone: cardiovascular protection Brown NJCirculation 2003[May]; 107 (19): 2512-8Data from animal studies and clinical trials indicate that aldosterone causes cardiovascular and renal injury through mineralocorticoid receptor-dependent mechanisms. However, although aldosterone receptor antagonism reduces mortality in patients with congestive heart failure, the progestational and antiandrogenic side effects of the nonspecific aldosterone receptor antagonist, spironolactone, have limited its usefulness in the treatment of hypertension. This review provides an overview of the pharmacology, efficacy, and safety of a new, more selective aldosterone receptor antagonist, eplerenone, in the context of emerging concepts of the role of aldosterone in cardiovascular toxicity.|Aldosterone/pharmacology/physiology[MESH]|Animals[MESH]|Cardiovascular Diseases/*drug therapy/physiopathology[MESH]|Cardiovascular System/*drug effects/physiopathology[MESH]|Disease Models, Animal[MESH]|Eplerenone[MESH]|Humans[MESH]|Hypertension/*drug therapy/physiopathology[MESH]|Mineralocorticoid Receptor Antagonists/adverse effects/pharmacology/*therapeutic use[MESH]|Renin-Angiotensin System/drug effects[MESH]|Spironolactone/adverse effects/*analogs & derivatives/pharmacology/*therapeutic use[MESH]|Treatment Outcome[MESH] |